SPECTRUM: Month 6 results from the first global real-world study of aflibercept 8 mg in patients with previously treated neovascular age-related macular degeneration

Andreas Stahl,[1] Clare Bailey,[2] Clemens Lange,[3,4] Varun Chaudhary,[5] Paolo Lanzetta,[6,7] Hassiba Oubraham,[8] Martin Kirchner,[9] Tobias Machewitz,[10] Helmut Allmeier,[11] Xin Zhang,[11] Zoran Hasanbasic,[11] Marion R. Munk,[12,13,14] Aude Ambresin,[15] on behalf of the SPECTRUM study investigators

[1]Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany; [2]Department of Ophthalmology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK; [3]Eye Center, Faculty of Medicine, Albert-Ludwig University Freiburg, Freiburg, Germany; [4]Department of Ophthalmology, St Franziskus Hospital, Münster, Germany; [5]Department of Surgery, McMaster University, Hamilton, ON, Canada; [6]Department of Medicine–Ophthalmology, University of Udine, Udine, Italy; [7]Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Milan, Italy; [8]Centre OPHTA-45, Montargis, France; [9]Bayer AG, Leverkusen, Germany; [10]Bayer AG, Berlin, Germany; [11]Bayer Consumer Care AG, Basel, Switzerland; [12]Augenarzt Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland; [13]Department of Ophthalmology, University Hospital Bern, Bern, Switzerland; [14]Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; [15]Swiss Visio Montchoisi, Lausanne, Switzerland

Presented at the 25th European Society of Retina Specialists (EURETINA), Paris, France, September 4–7, 2025

Disclosures

- Andreas Stahl: Consultant for Allergan, Apellis, Bayer, Novartis, and Roche
- CB: Received honoraria from Alimera Sciences, Apellis, Bayer, and Roche; and has served on advisory boards for Apellis, Bayer, Boehringer Ingelheim, Janssen, and Roche. CL: Receives honoraria from Apellis, Bayer, Biogen, and Novartis. VC: Consulting fees from EyePoint Pharmaceuticals; receives grants from Bayer, Novartis, and Roche; and serves on advisory boards for Apellis, Bayer, Boehringer Ingelheim, EyePoint Pharmaceuticals, Novartis, and Roche. PL: Consultant for Aerie Pharmaceuticals, Allergan, Annexon, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, Eyepoint, Genentech, I-Care, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche. HO: Consultant for AbbVie, Bayer, Novartis, and Roche. MK and TM: Employees of Bayer AG. HA, XZ, and ZH: Employees of Bayer Consumer Care AG. MRM: Consultant for AbbVie, Alcon, Alimera, Allergan, Amgen, Apellis Pharmaceuticals, Astellas, Aviceda Therapeutics, Bayer, Boehringer Ingelheim, Dandelione, Eyegnos Consulting, EyePoint Pharmaceuticals, Evolve Medical Education, GenSight Biologics, Isarna Therapeutics, Iveric Bio, Kubota, LumiThera, Novartis, Oculis, OD-OS, ONL Therapeutics, OcuTerra Therapeutics, RetinAI, Roche, UBS analytics, and Zeiss; AA: Consulting fees from Apellis, Bayer, Novartis, and Roche
- The SPECTRUM study (NCT06075147) was sponsored by Bayer Consumer Care AG, Basel, Switzerland
- The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation
- Medical writing support, under the direction of the authors, was provided by ApotheCom and funded by Bayer Consumer Care AG (Basel, Switzerland), in accordance with Good Publication Practice (GPP) guidance (Ann Intern Med. 2022;175:1298–1304)

SPECTRUM: Global real-world study of aflibercept 8 mg

A 24-month, non-interventional country and global cohort study planned in 18 countries

2 indications, 4 patient cohorts

Treatment-naïve nAMD and previously treated nAMD
Treatment-naïve DME and previously treated DME

Primary endpoint: Change in VA from BL to Month 12

Patient enrollment to date:

1100/1110 in the PT nAMD cohort and 3463 overall



Secondary endpoints include:

- Change in VA and CRT from BL to Month 6
- Number of injections, visits, and safety from BL to Month 6

BL, baseline; CRT, central retinal thickness; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; PT, previously treated; VA, visual acuity.

Baseline characteristics: Previously treated nAMD

Month 6 analysis of the first ~150 patients enrolled[a]

Previous nAMD medication



FAS, n	148
Age (years)	79.4±8.4
Median (min, max) time from nAMD diagnosis (months)	34.2 (1.3, 210.3)
Baseline VA (ETDRS letters)	63.0±19.3
Baseline CRT (µm)	320±109

MNV type[b]



Sex



Race[c]



FAS. Percentages may not add up to 100 due to rounding. [a]Data are mean±SD unless otherwise indicated. [b]Mixed refers to Type 1 and Type 2 MNV combined. [c]Data on race were collected for Australia, Canada, Germany, Italy, Japan, Portugal, South Korea, Saudi Arabia, Spain, Switzerland, United Arab Emirates, and the UK only. ETDRS, Early Treatment Diabetic Retinopathy Study; FAS, full analysis set; Max, maximum; Min, minimum; MNV, macular neovascularization; N/A, not applicable; SD, standard deviation; UK, United Kingdom.

VA through Month 6

Absolute VA



Mean change in VA



Patients received a mean of 4.4 injections up to Day 210 from baseline

FAS, LOCF (n=148). Missing values were imputed with the LOCF approach. Error bars are 95% CI.
Week 4 = visits closest to 28 (14–42) days after BL, Week 8 = visits closest to 56 (43–70) days after BL, Week 24 = visits closest to 180 (150–210) days after BL.
CI, confidence interval; LOCF, last observation carried forward.

Mean change in VA through Month 6 grouped by baseline VA

FAS, LOCF. Values have been rounded to the nearest decimal point. Error bars are 95% CI. W, week.

CRT through Month 6



Timepoint	Mean change (95% CI) from baseline (LOCF)
Week 4	−48 (−77, −20)
Week 8	−41 (−63, −18)
Week 24	−31 (−50, −13)



FAS, LOCF (n=148). Missing values were imputed with the LOCF approach. Error bars are 95% CI.

[a]In patients with a CRT assessment at Week 4 and Week 8, the mean change in CRT at Week 4 and Week 8 stratified by baseline CRT was −21 and −27 µm for those with a baseline CRT of <400, and −153 and −92 µm for those with a baseline CRT of ≥400 µm, respectively.

Proportion of patients without SRF or IRF through Month 6[a]



FAS, LOCF. Missing values were imputed with the LOCF approach. Values have been rounded to the nearest decimal point. Based on instructions in the case report form, fluid data were collected during a macular assessment (6 mm) per investigator discretion. [a]Calculated based on the number of patients assessed at each timepoint.
IRF, intraretinal fluid; SRF, subretinal fluid.

Safety overview: Adverse events

Ocular TEAEs	Total (N=150)
Any ocular TEAEs in the study eye,[a] n (%)	10 (6.7)
Any serious ocular TEAEs, n (%)	1 (0.7)
Non-ocular TEAEs	**Total (N=150)**
Any non-ocular TEAEs, n (%)	5 (3.3)
Any serious non-ocular TEAEs, n (%)	1 (0.7)

SAF. [a]The eye treated with aflibercept 8 mg was considered to be the study eye; if aflibercept 8 mg treatment was decided simultaneously for both eyes, the study eye was considered to be the worse eye per the discretion of the attending physician. SAF, safety analysis set; TEAE, treatment-emergent adverse event.

Month 6 results from SPECTRUM support the real-world effectiveness and safety of aflibercept 8 mg in patients with previously treated nAMD

More than 3400 patients enrolled in SPECTRUM across all 18 countries to date

More than 1100 patients enrolled in the previously treated nAMD cohort across 13 countries to date

Clinical and safety outcomes at Month 6

- Stable VA and improved CRT following switch to aflibercept 8 mg
- Improved IRF and SRF
- No new safety signals identified

Treatment exposure

- Results achieved with a mean of 4.4 injections up to Day 210 from BL
- Consistent with extending dosing intervals maintained through Week 48 in PULSAR[1]

As the first global real-world study of aflibercept 8 mg, Month 6 results from SPECTRUM will help to inform clinical management of previously treated nAMD in patients receiving aflibercept 8 mg

Month 12 and Month 24 analyses are on track

1. Lanzetta P, et al. Lancet. 2024;403:1141–1152.